ALGN:NGS-Align Technology Inc.

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 305.7

Change

0.00 (0.00)%

Market Cap

USD 7.53B

Volume

0.48M

Analyst Target

USD 339.13
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Align Technology Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM digital services used in dentistry, orthodontics, and dental records storage. Its segments are Clear Aligner and Scanners & Services.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-06-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABMD ABIOMED Inc.

N/A

USD 11.90B
PODD Insulet Corporation

N/A

USD 7.18B
IART Integra LifeSciences Holdings ..

N/A

USD 4.64B
VWR VWR Corporation

N/A

USD 4.38B
TNDM Tandem Diabetes Care Inc.

N/A

USD 3.70B
LIVN LivaNova PLC

N/A

USD 3.51B
WMGI Wright Medical Group N.V.

N/A

USD 3.37B
NUVA NuVasive Inc.

N/A

USD 2.96B
CNMD CONMED Corporation

N/A

USD 2.49B
ZLTQ ZELTIQ Aesthetics Inc.

N/A

USD 2.28B

ETFs Containing ALGN

PTH Invesco DWA Healthcare Mo.. 3.84 % 0.60 %

N/A

USD 0.14B
ZHU:CA BMO Equal Weight US Healt.. 2.04 % 0.00 %

N/A

CAD 4.61M
QQQE Direxion NASDAQ-100 Equal.. 1.22 % 0.35 %

N/A

USD 0.23B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 45.97% 86% B 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.97% 86% B 88% B+
Trailing 12 Months  
Capital Gain -15.71% 59% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.71% 59% F 44% F
Trailing 5 Years  
Capital Gain 500.00% 91% A- 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 500.00% 91% A- 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 59.26% 89% B+ 95% A
Dividend Return 59.26% 89% B+ 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.01% 37% F 17% F
Risk Adjusted Return 111.79% 93% A 93% A
Market Capitalization 7.53B 100% A+ 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.90 15% F 7% F
Price/Book Ratio 20.45 10% F 4% F
Price / Cash Flow Ratio 11.63 11% F 6% F
Price/Free Cash Flow Ratio 73.84 5% F 5% F
Management Effectiveness  
Return on Equity 33.41% 84% B 91% A-
Return on Invested Capital 38.94% 87% B+ 94% A
Return on Assets 20.85% 97% A+ 97% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.